Drugs / SAR445419
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05712278 | Jun 2023 → Feb 2024 | acute myeloid leukemia | Sanofi | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05726682 | Oct 2024 → Feb 2027 | disease related to hematopoietic stem cell transplant | Sanofi | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR445419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05726682 ↗ |
| Modality | Cell therapy | “SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product” PMID 41963545 ↗ Apr 2026 |
| Route | Intravenous | “participants received six intravenous SAR445419” PMID 41963545 ↗ Apr 2026 |